argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
June 17, 2024 01:00 ET
|
argenx SE
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next...
Indonesia Stock Exchange Partners with Nasdaq to Upgrade Market Infrastructure
June 17, 2024 01:00 ET
|
Nasdaq, Inc.
Technology partnership will further enhance overall resilience and integrity of the exchange, while supporting the rapid deployment of new products and services Scalable trading platform will...
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
June 17, 2024 01:00 ET
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
June 16, 2024 20:00 ET
|
HUTCHMED (China) Limited
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of...
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
June 16, 2024 06:10 ET
|
Regeneron Pharmaceuticals, Inc.
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously...
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
June 16, 2024 05:30 ET
|
Nurix Therapeutics, Inc.
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
June 15, 2024 08:45 ET
|
Agios Pharmaceuticals, Inc.
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights...
First Guaranty Bancshares, Inc. Declares 124th Consecutive Quarterly Cash Dividend to Shareholders
June 14, 2024 18:48 ET
|
First Guaranty Bank
HAMMOND, La., June 14, 2024 (GLOBE NEWSWIRE) -- On June 14, 2024 the Board of Directors of First Guaranty Bancshares, Inc. (“First Guaranty”) declared a quarterly cash dividend on First Guaranty’s...
ArrowMark Financial Corp. Announces Q1 2024 Results and Cash Distribution of $0.45 per Share for the Second Quarter 2024
June 14, 2024 17:30 ET
|
ArrowMark Financial Corp.
DENVER, June 14, 2024 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp. (Nasdaq: BANX) ("ArrowMark Financial" or the "Company"), an SEC registered closed-end management investment company, today...
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
June 14, 2024 16:54 ET
|
ASLAN PHARMACEUTICALS LIMITED
SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company...